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Abstract
Background: Accumulation of mitochondrial DNA (mtDNA) damage could enhance the frequency of
mitochondrial mutations and promote a variety of mitochondria-related diseases, including cancer. However, the
mechanism(s) involved are not fully understood.
Methods: Quantitative extended length PCR was used to compare mtDNA and nDNA damage in human lung H1299
cells expressing WT Bcl2 or vector-only control. mtAPE1 endonuclease activity was analyzed by AP oligonucleotide assay.
mtDNA mutation was measured by single molecule PCR. Subcellular localization of Bcl2 and APE1 was analyzed by
subcellular fractionation.
Results: Bcl2, an anti-apoptotic molecule and oncoprotein, effectively inhibits the endonuclease activity of mitochondrial
APE1 (mtAPE1), leading to significant retardation of mtDNA repair and enhanced frequency of mtDNA mutations
following exposure of cells to hydrogen peroxide (H2O2) or nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK, a carcinogen in cigarette smoke). Inversely, depletion of endogenous Bcl2 by RNA interference increases mtAPE1
endonuclease activity leading to accelerated mtDNA repair and decreased mtDNA mutation. Higher levels of mtAPE1
were observed in human lung cancer cells than in normal human bronchial epithelial cells (i.e. BEAS-2B). Bcl2 partially
co-localizes with APE1 in the mitochondria of human lung cancer cells. Bcl2 directly interacts with mtAPE1 via its BH
domains. Removal of any of the BH domains from Bcl2 abolishes Bcl2’s capacity to interact with mtAPE1 as well as its
inhibitory effects on mtAPE1 activity and mtDNA repair.
Conclusions: Based our findings, we propose that Bcl2 suppression of mtDNA repair occurs through direct interaction
with mtAPE1 and inhibition of its endonuclease activity in mitochondria, which may contribute to enhanced mtDNA
mutations and carcinogenesis.
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Background
Mitochondria contain their own genome (i.e. mitochondrial
DNA, mtDNA), which comprises a small, self-replicating
DNA molecule present in multiple copies in the mitochon-
drial matrix [1]. The human mitochondrial genome is a tiny
16.6 kb circle containing only 37 genes. Thirteen of these
genes encode proteins, and the remaining 24 consist of 2
ribosomal RNAs (rRNAs) and 22 tRNAs that are used for
translation of those 13 polypeptides [2]. In contrast to
nuclear DNA (nDNA), mtDNA is uninterruptedly repli-
cated even in terminally differentiated cells. mtDNA is
much more susceptible to oxidative damage than the
nuclear genome, presumably because it lacks protective
histones and due to its proximity to reactive oxygen species
(ROS) endogenously generated by the mitochondrial
electron transport complexes [3, 4]. Such damage includes
several dozen oxidized bases, apurinic/apyrimidinic (AP)
sites, and oxidation products of AP sites leading to DNA
strand breaks [5]. Nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK) is the most potent carcinogenic
constituent in cigarette smoke that can induce DNA
damage, including AP sites in nDNA [6–8]. The mtDNA is
very sensitive to oxidative stress-induced damage [9]. It is
currently unclear whether NNK induces mtDNA damage.
The rate of mtDNA mutations can be more than two
orders of magnitude higher than that of nDNA [10].
Somatic mutations of mtDNA are potentially more
harmful for cell functions compared to somatic damages
of nDNA. Consequently, the DNA repair systems in the
mitochondria may be more important than in the nuclei,
especially in non-dividing cells [11]. Accumulated
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mtDNA mutations have been proposed to be associated
with cancer [12], neurodegenerative disorders [13],
diabetes [14], and premature aging [15–18]. Human
apurinic/apyrimidinic endonuclease 1 (APE1) is a major
component of the base excision repair (BER) pathway of
AP sites [19]. Two functionally independent domains of
the protein were characterized and determined to per-
form two different activities: the N terminus domain is
principally defined to possess redox activity, whereas the
C terminus region exerts its enzymatic activity on the
repair of AP sites [19, 20]. APE1 specifically binds to AP
sites and initiates repair by incision of the 5’phospho-
diester bond to generate a 3’ hydroxyl terminus, which
serves as the primer required for gap-filling in the BER
repair pathway [19]. In addition to nuclear localization,
APE1 has been reported to be localized in mitochondria
in various types of cells, including lung cancer cells
[19, 21–23]. Because repair of oxidative mtDNA damage
also occurs through the BER pathway in various cell types
[24, 25], APE1 has been considered to play a central role
in repairing AP sites in both nDNA and mtDNA [26].
Bcl2 is a major anti-apoptotic molecule in the Bcl2 family
that can suppress apoptosis to prolong cell survival [27]. In
addition to its survival activity, Bcl2 can also inhibit the
repair of various types of DNA damage, including AP sites
[7] and DNA double strand breaks (DSBs) [28], by nega-
tively regulating APE1-mediated BER and Ku-mediated
nonhomologous end joining (NHEJ) pathways. We previ-
ously demonstrated that Bcl2 potently suppresses the repair
of NNK-induced AP sites in the nucleus through direct
interaction with nuclear APE1 and subsequent inhibition of
its endonuclease activity [7, 29]. Since the majority of Bcl2
is localized in mitochondria [30–32], Bcl2 may also play an
important role in the regulation of mtDNA repair. In the
present report, we show that Bcl2 suppresses mtDNA
repair through direct interaction with APE1 in mitochon-
dria via its BH domains and inhibition of mtAPE1 endo-
nuclease activity, leading to increased frequency of mtDNA
mutations following exposure of cells to H2O2 or NNK.
These findings identify a novel role for Bcl2 in regulating
mtDNA repair and mtDNA mutagenesis.
Methods
Materials
Bcl2, APE1, PCNA, prohibitin and tubulin antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). MTT cell growth kit was obtained from Sigma (St.
Louis, MO). QIAamp DNA isolation kit was purchased
from Qiagen (Chatsworth, CA). 4,6-diamidino-2-pheny-
lindole (DAPI), QD605 goat anti-rabbit IgG conjugate
(red), QD705 goat anti-mouse IgG conjugate (green) and
Pico Green dsDNA Quantitation kit were obtained from
Invitrogen (Carlsbad, CA). HEX-5ʹ-end-labeled 26-mer
duplex oligonucleotide (5ʹ-AAT TCA CCG GTA CCF
CCT AGA ATT CG-3’) was purchased from IDT
Technologies (Coralville, IA). LA PCR Kit and TaKaRa
ExTak PCR kit were obtained from Clontech Laboratories,
Inc (Mountain View, CA). All of the reagents used were
obtained from commercial sources unless otherwise stated.
Cell lines, plasmids, and transfections
H1299 and H460 cells were maintained in RPMI 1640
with 5 % bovine serum and 5 % fetal bovine serum. These
cell lines were employed for the described experiments
without further authentication. WT and Bcl2 BH deletion
mutants were created and stably expressed in H1299 cells
as previously described [28]. The expression levels of
exogenous Bcl2 were analyzed by Western blot analysis.
Three separate clones expressing similar amounts of
exogenous Bcl2 were selected for further analysis.
Preparation of cell lysates
Cells were washed with 1xPBS and resuspended in ice-
cold 1 % CHAPS lysis buffer (1 % CHAPS, 50 mM Tris
[pH 7.6], 120 mM NaCl, 1 mM EDTA, 1 mM Na3VO4,
50 mM NaF, and 1 mM β-mercaptoethanol) with a cock-
tail of protease inhibitors (EMD Biosciences). Cells were
lysed by sonication and centrifuged at 14,000 × g for
10 min at 4 °C. The resulting supernatant was collected
as the total cell lysate.
Subcellular fractionation
Cells were washed twice in PBS and then resuspended in
isotonic mitochondrial buffer (210 mM mannitol,
70 mM sucrose, 1 mM EGTA, 10 mM Hepes, pH 7.5)
containing protease inhibitor mixture set I (Calbiochem).
The resuspended cells were homogenized with a poly-
tron homogenizer operating for four bursts of 10 s each
at a setting of 5. The mitochondrial, light membrane,
cytosol and nuclear fractions were isolated as we previ-
ously described [33]. Protein from each fraction was
analyzed by Western blot.
Quantum dot-based immunofluorescence (QD-IF)
QD-IF was performed as described previously [34]. Briefly,
cells were washed with 1 × PBS, fixed with cold methanol
and acetone (1:1) for 10 min, and then blocked with 1 %
normal goat serum for 60 min at room temperature. The
cells were incubated simultaneously with mouse Bcl2 and
rabbit APE1 primary antibody overnight at 4 °C. After
washing, the samples were incubated with QD secondary
antibody conjugates (QD 605 goat F(ab’)2 anti-rabbit IgG,
red; QD 705 goat F(ab’)2 anti-mouse IgG, green 1:50 dilu-
tion) in a cocktail solution at room temperature for
60 min. Cell nuclei were counterstained with DAPI.
Mouse and rabbit IgG were used as negative controls. QD
imaging and quantification procedures were performed as
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described previously [34]. The Nuance™ fluorescence
microscope system (CRi consolidated with Caliper, a
PerkinElmer company, Hopkinton, MA) was used for
quantification of the QD signals. All cubed image files
were collected from culture cells at 10 nm wavelength
intervals from 420–720 nm, with an auto exposure time
per wavelength interval at 200 ~ 400× magnification.
Taking the cube with a long wavelength band pass filter
allowed transmission of all emission wavelengths above
420 nm. Both separated and combined QD images were
obtained after establishing the QD spectral library and
unmixing the image cube. For each cell sample, 10 cubes
were taken. The background signal was removed for accur-
ate quantification of the QD signals. Cells were observed
and signal was quantified by an Olympus microscope IX71
with a CRi Nuance spectral imaging and quantifying system
(CRi Inc., Woburn, MA) [34, 35]. The co-localization of
Bcl2 and APE1 was quantified by Nuance imaging software
(Caliper/PerkinElmer), 10 randomly selected fields on the
cell slides were calculated.
AP oligonucleotide assay for mtAPE1 endonuclease
activity
Intact mitochondria were isolated as we described previ-
ously [36]. The isolated mitochondria from cells were
resuspended in 0.5 % NP-40 lysis buffer and rocked for
60 min prior to centrifugation at 17,530 × g for 10 min at
4 °C. The resulting supernatant was used as mitochondrial
extract for the mtAPE1 activity assay. APE1 activity was
analyzed by measuring incision of a HEX-5ʹ-end-labeled
26-mer duplex oligonucleotide substrate containing a
synthetic tetrahydrofuran (THF, F) AP site as described
previously [37]. Reaction mixtures (20 μl) containing 1 μg
mitochondrial extract, 5 pmol of HEX-5ʹ end labeled,
double-stranded THF oligonucleotide, 50 mM HEPES,
50 mM KCl, 10 mM MgCl2, 1 μg/ml BSA, and 0.05 %
Triton X-100 (pH 7.5) were incubated at 37 °C for 15 min.
The reaction was stopped by the addition of 20 μl form-
amide and 10 mM EDTA. Samples were separated by a
20 % polyacrylamide gel containing 7 M urea. The bands
of 14-mer (cleavage product) and 26-mer (uncleaved
substrate) oligonucleotides were visualized by Typhoon
9410 imager system and quantified using ImageQuant™
software (Molecular Dynamics). The AP endonuclease
activity was calculated by the formula: 14 ‐mer/(14 ‐mer
+ 26 ‐mer) × 100.
Analysis of mtDNA and nDNA damage by quantitative
extended length PCR (QPCR)
mtDNA and nDNA damage was analyzed by QPCR as
described previously [9, 38]. Briefly, cells in serum-free-
medium were treated with H2O2 and NNK for 1 h. Cells
were then washed three times and incubated in normal
medium for various times. DNA was isolated with the
QIAamp DNA isolation kit for QXLPCR using LA PCR
Kit. Primers for mtDNA (16.2 kb): 5’ TGA GGC CAA
ATA TCA TTC TGA GGG GC 3’ (sense); 5’ TTT CAT
CAT GCG GAG ATG TTG GAT GG 3’ (antisense).
Primers for the β-globin gene of nDNA (17.7 kb): 5’
TTG AGA CGC ATG AGA CGT GCA G 3’ (sense); 5’
GCA CTG GCT TAG GAG TTG GAC T 3’ (antisense).
The PCR product was quantified by Pico Green dsDNA
Quantitation kit as described [38].
MTT cell proliferation assay
Cells were treated with H2O2 (100 μM) or NNK (200 μM)
in serum-free medium for 60 min, and then washed three
times with 1 × PBS. Cells were then allowed to recover in
regular medium for 24 h. Cells were incubated with
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide) at a final concentration of 2.0 μg/ml
during the last hour of the recovery period, followed
by lysis in 20 % SDS and 50 % DMSO in 1 × PBS buffer.
Samples were measured at an absorbance of 570 nm.
MTT reduction for treated samples was then normalized
to that of non-treated control samples.
Cell cycle analysis
After treatment with H2O2 or NNK, cells were washed
once with ice-cold PBS and resuspended in 100 μL of ice-
cold PBS. Then 900 μL of cold methanol was added to the
cells, mixed gently and then incubated on ice or in a −20 °
C freezer for at least 30 min. Cells were washed once with
PBS and resuspended in 500 μL PBS. RNAse (100 μg/mL)
was added and incubated at room temperature for 60 min.
Next, 500 μL of 0.1 mg/mL propidium iodide (PI) was
added to cells and incubated at room temperature for
30 min. Cell cycle was analyzed by flow cytometry as
described previously [39].
Analysis of mtDNA mutation by single molecule PCR
Single molecule PCR was applied to analyze mtDNA
mutation as described [40, 41]. Cells were treated with
100 μM H2O2 or 200 μM NNK for 60 min. Cells were
washed 3 times and cultured in fresh medium for 15 days.
Total DNA was isolated with the QIAamp DNA isolation
kit and diluted to 1:106. PCR was carried out using
TaKaRa ExTak PCR system according to the manufac-
turer’s instructions. First round PCR was carried out for
40 cycles (95 °C for 20 s, 68 °C for 2 min). 3 μl of PCR
mixture was then used for second round PCR (additional
25 cycles). Primers for first round PCR: 5’ATT CTA ACC
TGA ATC GGA GG 3’ and 5’ GAT GCT TGC ATG TGT
AAT CT 3’; Primers for second round PCR: 5’AGG ACA
ACC AGT AAG CTA CCC T 3’ and 5’ ACT AAG AGC
TAA TAG AAA G 3’. The final PCR products were
subjected to electrophoresis on 0.8 % agarose gel and
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purified for DNA sequencing. Mutation load was calcu-
lated as described [40, 41].
Bcl2 silencing
Bcl2 shRNA and its control shRNA were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Hairpin
sequence of Bcl2 RNA: GAT CCG TGT GGA TGA CTG
AGT ACC TGA TTC AAG AGA TCA GGG ACT CAG
TCA TCC ACA TTT TTG. Hairpin sequence of control
shRNA: GAT CCG GAA CGG CATC AAG GTG AAC
TTC AAG AGA GTT CAC CTT GAT GCC GTT CTT
TTT G. For pseudovirus production, Bcl2 shRNA or con-
trol shRNA was cotransfected into 293FT cells with lenti-
vector packaging plasmid mixture (System Biosciences,
CA) using NanoJuice transfection kit (EMD Chemical,
Inc.) as described [42]. After 48 h, the virus-containing
media were harvested by centrifugation at 20,000 × g.
H460 cells were infected with the virus-containing media
in the presence of polybrene (8 μg/ml) for 24 h following
which stable positive clones were selected using 1 μg /ml
puromycin. The levels of Bcl2 expression were analyzed
by Western blot. Specific silencing of the targeted Bcl2
gene was confirmed by at least three independent
experiments.
Statistical analysis
Significant differences between two groups were analyzed
using two-sided unpaired Student’s t-test. A p value < 0.05
was considered statistically significant.
Results
mtDNA is more sensitive than nDNA to NNK or H2O2-
induced damage
To test whether NNK induces mtDNA damage, we
employed quantitative amplification (QPCR) of long DNA
fragments as previously described [9]. H2O2 was used as a
positive control since its ability to induce mtDNA damage
is well established [9]. mtDNA (a 16.2-kb mtDNA frag-
ment) and nDNA (a 17.7-kb fragment from the β-globin
loci) were analyzed by QPCR following exposure of
H1299 cells to increasing concentrations of H2O2 or
NNK. Results revealed that, in addition to H2O2, NNK
also induced mtDNA damage in a dose-dependent man-
ner (Fig. 1a, b). Importantly, mtDNA was more sensitive
than nDNA to NNK or H2O2-induced damage (Fig. 1a, b).
Similar experiments were also performed in another
human lung cancer cell line (i.e. H460) and yielded similar
results (Additional file 1: Figure S1), suggesting that the
effect of NNK or H2O2 on mtDNA and nDNA is a general
reaction and not a cell type-specific phenomenon. This
supports and extends the findings of a previous report [9].
To rule out the possibility of mtDNA pseudogenes ampli-
fied by the mitochondrial primers used, QPCR experiments
using the same primers were performed in DU145 cells and
the mtDNA deficient DU145ρ0 cells [43]. Results con-
firmed that mtDNA was observed only in DU145 cells but
not in DU145 DU145ρ0 cells (Additional file 1: Figure S2).
Expression of Bcl2 inhibits mtDNA repair induced by
H2O2 or NNK leading to increased frequency of mtDNA
mutations
Bcl-2 has been implicated in the negative regulation of
repair of various types of DNA damage in the nucleus
[7, 28, 29, 44]. It remains unknown whether Bcl2 affects
mtDNA repair since Bcl2 is mainly localized in
Fig. 1 Mitochondrial DNA (mtDNA) is more vulnerable than nuclear
DNA (nDNA) to damage induced by H2O2 or NNK. a and b. H1299
cells were treated with increasing concentrations of H2O2 (a) or NNK
(b) for 60 min. The mtDNA or nDNA damage was measured by
QXLPCR and quantified by Pico Green dsDNA Quantitation kit as
described in “Methods”. Quantification data are mean ± SD from
three independent experiments
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mitochondria [45]. To determine whether Bcl2 regulates
mtDNA repair, H1299 cells expressing Bcl2 or vector-only
control (Fig. 2a) were treated with H2O2 (100 μM) or
NNK (200 μM) for 60 min. More than 90 % of the cells
remained alive for a short time (60 min) following treat-
ment at the doses used (data not shown). Cells were then
washed and incubated in normal cell culture medium for
various times as indicated. mtDNA damage was analyzed
by QPCR. Intriguingly, there was no significant difference
in mtDNA damage between cells expressing Bcl2 and
vector control cells initially following H2O2 or NNK
exposure (Fig. 2b). As compared to vector-only control
cells, the repair of H2O2 or NNK-induced mtDNA
damage was significantly delayed in cells expressing WT
Fig. 2 Bcl2 inhibits mtDNA repair in association with increased frequency of mtDNA mutations. a. Levels of Bcl2 and APE1 were analyzed by
Western blot in H1299 cells expressing WT Bcl2 and vector-only control. b and c. H1299 cells expressing WT Bcl2 and vector-only control were
treated with 100 μM H2O2 (b) and 200 μM NNK (c) for 60 min. Cells were then washed three times and incubated in fresh culture medium for
various times as indicated. mtDNA damage or mtDNA mutation was analyzed as described in “Methods”. Quantification data are mean ± SD from
three independent experiments
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Bcl2 (i.e. 48 h vs. 24 h) (Fig. 2b, c), indicating that Bcl2
inhibits mtDNA repair. Additionally, the effect of H2O2 or
NNK on cell proliferation or cell cycle was analyzed.
Results indicate that H2O2 or NNK at 100 μM reduced
proliferation and enhanced the proportion of H1299 and
H460 cells in S and G2 phases (Additional file 1: Figure S3).
It has been previously reported that the APE1 expression
level varies within the cell cycle in NIH 3 T3 cells and
that APE1 regulates the proliferation and migration of
pancreatic cancer cells [46, 47]. It is possible that, in
addition to mtDNA repair, APE1 may play a role in regu-
lating cell proliferation or cell cycle after exposure of cells
to H2O2 or NNK. To explore whether Bcl2 inhibition of
mtDNA repair enhances the frequency of mtDNA muta-
tions, single molecule PCR was employed for the analysis
of mtDNA mutations as described in Materials and
Methods [41]. The advantage of single molecule PCR is
that PCR driven-errors are excluded [40, 41], thus, the se-
quence results represent the true mtDNA mutation load.
As shown in Fig. 2b and c, right panels, expression of Bcl2
Fig. 3 Bcl2 is co-localized with APE1 via BH domains in mitochondria. a. Subcellular fractionation was performed in H460 and BEAS-2B cells to
isolate heavy membrane (HM), light membrane (LM), cytosol (Cyt) and nuclear (Nuc) fractions. Bcl2 and APE1 in each fraction were analyzed by
Western blot. Prohibitin and PCNA were used as mitochondrial and nuclear markers, respectively. b. APE1 and Bcl2 were analyzed in H460 cells
expressing high levels of endogenous Bcl2 and APE1 using QD-IHF and quantified as described in “Methods”. Co-localization of APE1 and Bcl2 in
mitochondria was analyzed and quantified with Nuance software in 10 randomly selected fields
Xie et al. BMC Cancer  (2015) 15:586 Page 6 of 12
not only enhanced mtDNA mutations but also signifi-
cantly increased H2O2 or NNK-induced mtDNA mutation
load.
Bcl2 co-localizes and interacts with mtAPE1 via BH
domains on mitochondrial membranes
APE1 functions as an AP site repair enzyme and is mainly
localized in the nucleus [19, 48]. A previous study indi-
cated that APE1 has “extranuclear” localizations, including
mitochondria and endoplasmic reticulum (ER), in various
cells, including lung cancer, hepatocellular carcinoma
and colorectal carcinoma cells [19]. Intriguingly, the
extranuclear localization of APE1 is associated with
poor prognosis of patients with cancer [19, 49, 50].
Our data show that, in addition to the nucleus, significantly
higher levels of APE1 were observed in heavy membranes
(HM) that contain mitochondrial membranes, and light
membranes (LM) that contain ER in human lung cancer
H460 cells compared to normal human bronchial epithe-
lium (BEAS-2B) cells (Fig. 3a). Intriguingly, in addition to
nuclear localization, APE1 also partially co-localized with
MitoTracker (Additional file 1: Figure S4), providing
additional evidence of mitochondrial localization of APE1
in human lung cancer cells. Because Bcl2 was found to
mainly localize in the HM fraction (Fig. 3a), this indicates
that APE1 may co-localize with Bcl2 in mitochondria.
Prohibitin, an exclusively mitochondrial protein [51], was
detected only in the HM fraction that contains mitochon-
drial membranes, while proliferating cell nuclear antigen
(PCNA), a nuclear marker [52], was detected exclusively in
the nuclear fraction (Nuc) (Fig. 3a), indicating that the
fractionation procedure did not cause cross-contamination
between these organelles.
To further confirm the co-localization of APE1 and
Bcl2, a quantum dot-based immunofluorescence (QD-IF)
technology was employed. Quantum dots (QDs) are nano-
scale particles made from inorganic semiconductors that
can produce different fluorescence signals depending on
their size and components [34]. The advantage of this
approach is that it allows for quantification of several
biomarkers simultaneously on the same tissue slide [53].
QD-IF studies revealed that APE1 is localized in both the
nucleus and cytoplasm in H460 cells because the extranu-
clear portion of APE1 could be clearly observed in the
merged image of APE1 and DAPI (Fig. 3b, upper right
panel). Analysis of QD images by Nuance imaging soft-
ware revealed that 24.67 % of APE1 was co-localized with
Bcl2 in the cytoplasm (mainly on mitochondria; Fig. 3b,
lower right panel). These findings suggest a potential role
of Bcl2 in regulating mtAPE1 function in mitochondria.
To investigate whether Bcl2 interacts with APE1 via its
BH domains on mitochondria, co-immunoprecipitation
(co-IP) experiments were performed in isolated mitochon-
drial extracts from H1299 cells expressing WT or each of
the BH deletion mutants using agarose-conjugated APE1
antibody. Intriguingly, APE1 interacted with WT Bcl2
protein but not with any of the BH-deleted Bcl2 mutants
in isolated mitochondrial extract (Fig. 4). These findings
demonstrate that mitochondrial APE1 is able to associate
with Bcl2 in a BH-domain dependent manner.
BH domains are required for the inhibitory effects of Bcl2
on mtAPE1 activity and mtDNA repair
To test whether Bcl2 affects mtAPE1 activity, mitochon-
drial extract was generated from H1299 cells expressing
WT or each of the BH deletion mutants and then incu-
bated with HEX-5ʹ-end-labeled 26-mer duplex oligo-
nucleotide substrate. APE1 activities in mitochondria
from H1299 cells expressing WT or each BH deletion
mutant were analyzed as described in “Materials and
Methods”. The cleaved 14-mer product fragment reflects
AP endonuclease activity while the uncleaved 26-mer
oligonucleotide correlates to lack of endonuclease activ-
ity. As shown in Fig. 5a, a decreased level of AP endo-
nuclease activity (i.e. smaller amount of cleaved 14-mer
product and greater amount of uncleaved 26-mer oligo-
nucleotide) was observed in the mitochondrial extract
from H1299 cells expressing WT Bcl2 when compared
to cells expressing each BH deletion mutant or vector-
only control. These findings suggest that mitochondrial
Bcl2 can suppress mtAPE1 activity. The inhibitory effect
Fig. 4 Bcl2 interacts with mtAPE1 via its BH domains in
mitochondrial extracts. Co-immunoprecipitation (co-IP) experiments
were performed in mitochondrial extracts isolated from H1299 cells
expressing WT or each of the Bcl2 deletion mutants using APE1
antibody. Normal rabbit IgG was used for negative control for co-IP.
APE1-associated Bcl2 and total mtAPE1 in mitochondrial extracts
were analyzed by Western blot
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of Bcl2 on mtAPE activity requires its BH domains (i.e.
APE1 binding site). Importantly, BH domains are also
required for Bcl2 suppression of mtDNA repair and
enhancement of mtDNA mutation frequency (Fig. 5b, c).
Depletion of endogenous Bcl2 by RNA interference
results in increased mtAPE1 activity and accelerated
mtDNA repair leading to reduced frequency of mtDNA
mutations
To test the physiological role of endogenous Bcl2 in
regulating mtAPE1 activity, mtDNA repair and mtDNA
mutation frequency, the relatively high levels of endogen-
ous Bcl2 in H460 cells were depleted by RNA interference
(RNAi) using Bcl2 shRNA as described in Materials and
Methods. Transfection of Bcl2 shRNA significantly re-
duced the expression level of endogenous Bcl2 by more
than 99 % in H460 cells (Fig. 6a). Control shRNA had no
effect on Bcl2 expression. Intriguingly, specific knock-
down of endogenous Bcl2 not only upregulated
mtAPE1 endonuclease activity (i.e. increased amount of
cleaved 14-mer product) but also accelerated mtDNA
repair in association with deceased frequency of mtDNA
Fig. 5 BH domains are required for Bcl2 suppression of mtAPE1 activity, mtDNA repair and enhancement of mtDNA mutations. a. Expression
levels of Bcl2 and APE1 in H1299 cells expressing WT or each Bcl2 deletion mutant were analyzed by Western blot. HEX-labeled 26-mer AP site
mimetic oligonucleotides (substrate) were incubated with mitochondrial extract isolated from H1299 cells expressing WT or each Bcl2 deletion
mutant. APE1 endonuclease activity (cleavage of substrate) was analyzed by Typhoon 9410 imager system as described in “Methods”. b and c.
H1299 cells expressing WT or each of the Bcl2 deletion mutants were treated with 100 μM H2O2 (b) and 200 μM NNK (c) for 60 min. Cells were
then washed three times and incubated in fresh culture medium for the indicated times. mtDNA damage or mtDNA mutation was analyzed as
described in “Methods”. Quantification data are mean ± SD from three independent experiments
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mutations (Fig. 6). These findings provide strong evidence
that physiologically expressed Bcl2 in cells is able to
suppress mtDNA repair and promote mtDNA mutation
through a mechanism involving the inhibition of mtAPE1
endonuclease activity.
Discussion
Mitochondria are key intracellular organelles that serve
as the powerhouse of eukaryotic cells. They are thus
involved in critical processes deciding cell fate that are
crucial for cell growth, survival and tumor development.
Mitochondrial DNA (mtDNA) is remarkably vulnerable
to oxidative or other genotoxic damage and displays a
significantly higher mutation rate (10- to 200-fold) com-
pared to the nuclear genome [54]. Numerous somatic
mutations in both the coding and control regions of
mtDNA have been extensively examined in a broad
range of primary human cancers, underscoring the fact
Fig. 6 Depletion of Bcl2 by RNAi enhances mtAPE1 activity and promotes mtDNA repair in association with deceased frequency of mtDNA
mutations. a. Bcl2 shRNA or control shRNA was transfected into H460 cells. Bcl2 expression was analyzed by Western blot. APE1 endonuclease
activity was compared in H460 cells expressing Bcl2 shRNA or control shRNA. b and c. H460 cells expressing Bcl2 shRNA or control shRNA were
treated with 100 μM H2O2 (b) and 200 μM NNK (c) for 60 min. Cells were then washed three times and incubated in fresh culture medium for
indicated times. mtDNA damage or mtDNA mutation was analyzed as described in “Methods”. Quantification data are mean ± SD from three
independent experiments
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that accumulation of mtDNA mutations may be a
critical factor in eliciting persistent mitochondrial
defects and consequently contributing to cancer initi-
ation and progression [55]. Intriguingly, accumulation of
mtDNA mutations may also contribute to tumor
metastasis [56]. However, the mechanisms of generating
these mtDNA mutations in the carcinogenic process
remain largely unknown, although it is known that
mtDNA is subjected to continuous oxidative attack by
free radicals [9].
NNK is one of the major carcinogens in tobacco. NNK
has been associated with various cancers in tobacco
users, especially lung cancer [57]. NNK can induce
oxidative DNA damage, including the generation of AP
sites in nDNA [58]. Our data show that, in addition to
nDNA, NNK can also induce mtDNA damage and
enhance mutation frequency in mtDNA (Figs. 1b and
2c). Intriguingly, mtDNA is more sensitive than nDNA
to NNK-induced damage (Fig. 1b), suggesting that NNK-
induced mtDNA damage and mutations may play a role
in mtDNA-related diseases, including the development
of various types of cancer.
Since the mtAPE1-mediated BER pathway is the main
DNA repair route present in mitochondria [59], inhibition
of mtAPE1-mediated mtDNA repair may lead to increased
frequency of mtDNA mutations in mitochondria. Our find-
ings reveal that expression of Bcl2 resulted in decreased
mtAPE1 activity in mitochondria leading to suppression of
mtDNA repair and accumulation of mtDNA mutations
following exposure of cells to H2O2 or NNK (Fig. 2).
Conversely, depletion of endogenous Bcl2 by RNAi
enhances mtAPE1 endonuclease activity and accelerates
mtDNA repair, which contributes to reduction of mtDNA
mutations (Fig. 6). These findings identify a novel function
of Bcl2. Bcl2 inhibition of mtDNA repair and enhancement
of mtDNA mutations may promote tumorigenesis follow-
ing exposure to carcinogens (i.e. NNK) or reactive oxygen
species. Nuclear respiration factor 1 (NRF1) is the main
factor regulating mitochondrial biogenesis and plays a
crucial role in regulating the expression of a broad range of
mitochondrial genes [60]. It has recently been reported that
APE1 functions as a coactivator of NRF1 and regulates
mitochondrial function through an NRF1-dependent
pathway. Specific knockdown of APE1 impairs NRF1
DNA-binding activity [60]. Thus, Bcl2 inhibition of APE1
may also reduce NRF1 activity, which may partially contrib-
ute to decreased mtDNA level following H202 or NNK
treatment. Further studies are required to demonstrate this
possibility.
Mitochondrial localization is thought to be required
for Bcl2 suppression of apoptosis and more than 90 % of
Bcl2 is localized in mitochondria [36, 61]. Since mtBcl2
is co-localized and interacts with mtAPE1 in mitochon-
dria (Figs. 3 and 4), this may explain how mitochondrial
Bcl2 (mtBcl2) has inhibitory effects on mtAPE1 activity
and mtDNA repair.
Bcl2 family members share homology in regions desig-
nated BH domains BH1, BH2, BH3, and BH4 [62]. All four
BH domains are necessary for the robust antiapoptotic
function of Bcl2 [28, 63, 64]. Since removal of any of these
BH domains eliminates the effects of Bcl2 on mtAPE1
binding, mtAPE1 activity, mtDNA repair and mtDNA
mutation (Figs. 4 and 5), this suggests that the interaction
between Bcl2 and mtAPE1 in mitochondria is essential for
Bcl2’s inhibitory effects on mtAPE1 activity and mtDNA re-
pair and consequently for promotion of mtDNA mutations
(Figs. 4 and 5). Thus, the oncogenic activity of Bcl2 may
also require its BH domains.
Conclusions
Here we have identified a previously unrecognized role of
Bcl2 in regulating mtDNA repair and mtDNA mutation
in human lung cancer cells. Bcl2 suppression of mtDNA
repair occurs through its interaction with mtAPE1 in
mitochondria via BH domains and subsequent suppres-
sion of mtAPE1 activity. Inhibition of mtDNA repair by
Bcl2 in association with enhanced frequency of mtDNA
damage may contribute to promotion of carcinogenesis
and/or progression of cancer.
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